Non-Small Cell Lung Cancer
Conditions
Brief summary
This randomized, double-blind, placebo-controlled study will evaluate the efficacy and safety of bevacizumab (Avastin) versus placebo in combination with carboplatin/paclitaxel in participants with advanced or recurrent non-squamous non-small cell lung cancer who have not received prior chemotherapy for advanced disease. Participants will be randomized to receive either bevacizumab 15 milligrams per kilogram (mg/kg) intravenously (IV) or placebo on Day 1 of each 3 week cycle, plus up to 6 cycles of carboplatin/paclitaxel. Anticipated time on study treatment is until disease progression or unacceptable toxicity occurs. After progression, participants in the bevacizumab arm may continue to receive bevacizumab in combination with approved second- and third-line treatment at the discretion of the investigator, up to the third progression.
Interventions
DRUGBevacizumab
Bevacizumab will be administered at 15 mg/kg IV on Day 1 of each 3-week cycle until disease progression or unacceptable toxicity.
DRUGCarboplatin
Carboplatin will be administered at area under the plasma concentration-time curve (AUC) 6.0 IV on Day 1 of each 3-week cycle, up to 6 cycles.
DRUGPaclitaxel
Paclitaxel will be administered at 175 milligrams per square meter (mg/m\^2) IV on Day 1 of each 3-week cycle, up to 6 cycles.
DRUGPlacebo
Bevacizumab matching placebo will be administered IV on Day 1 of each 3-week cycle until disease progression or unacceptable toxicity.
Sponsors
Hoffmann-La Roche
Study design
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
DOUBLE (Subject, Investigator)
Eligibility
Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No
Inclusion criteria
* Locally advanced (Stage IIIb not amenable for combined modality treatment), metastatic (Stage IV) or recurrent non-squamous non-small cell lung cancer * Eastern Cooperative Oncology Group (ECOG) performance status of 0-1 * Adequate hematological, renal and liver function
Exclusion criteria
* Prior chemotherapy or treatment with another systemic anti-cancer agent for the treatment of the participant's current stage of the disease (Stage IIIb, IV or recurrent disease) * Mixed non-small cell and small cell tumors or mixed adenosquamous carcinomas with a predominant squamous component * Evidence of tumor invading major blood vessels on imaging * Central nervous system (CNS) metastases, even if previously treated * History of hemoptysis in the 3 months prior to enrollment * History or evidence of inherited bleeding diathesis or coagulopathy * Uncontrolled hypertension and/or history of hypertensive crisis or hypertensive encephalopathy * Clinically significant cardiovascular or vascular disease * Malignancies other than non-small cell lung cancer within 5 years prior to randomization, except for adequately treated carcinoma in situ of the cervix, basal or squamous cell skin cancer, or localized prostate cancer or ductal carcinoma in situ treated surgically with curative intent
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Progression-Free Survival (PFS) as Assessed Using Response Evaluation Criteria in Solid Tumors Version 1.0 (RECIST v1.0) Criteria | Baseline up to death or disease progression, whichever occurs first (up to approximately 20 months) |
Secondary
| Measure | Time frame |
|---|---|
| Percentage of Participants Who are Alive at Year 1 | Year 1 |
| Percentage of Participants With Objective Response of Complete Response (CR) or Partial Response (PR) as Assessed Using RECIST v1.0 Criteria | Baseline up to death or disease progression, whichever occurs first (up to approximately 35 months) |
| Duration of Response as Assessed Using RECIST v1.0 Criteria | Baseline up to death or disease progression, whichever occurs first (up to approximately 35 months) |
| Percentage of Participants With Adverse Events | From baseline up to approximately 35 months |
| PFS as Assessed Using RECIST v1.0 Criteria in Subgroups Defined by Vascular Endothelial Growth Factor-A (VEGF-A) High/Low Level Expression at Baseline | Baseline up to death or disease progression, whichever occurs first (up to approximately 35 months) |
| Overall Survival (OS) | Baseline up to death (up to approximately 35 months) |
| OS in Subgroups Defined by VEGF-A High/Low Level Expression at Baseline | Baseline up to death (up to approximately 35 months) |
| OS in Subgroups Defined by VEGFR-2 High/Low Level Expression at Baseline | Baseline up to death (up to approximately 35 months) |
| Percentage of Participants With Objective Response of CR or PR as Assessed Using RECIST v1.0 Criteria in Subgroups Defined by VEGF-A High/Low Level Expression at Baseline | Baseline up to death or disease progression, whichever occurs first (up to approximately 35 months) |
| Percentage of Participants With Objective Response of CR or PR as Assessed Using RECIST v1.0 Criteria in Subgroups Defined by VEGFR-2 High/Low Level Expression at Baseline | Baseline up to death or disease progression, whichever occurs first (up to approximately 35 months) |
| PFS as Assessed Using RECIST v1.0 Criteria in Subgroups Defined by Vascular Endothelial Growth Factor Receptor 2 (VEGFR-2) High/Low Level Expression at Baseline | Baseline up to death or disease progression, whichever occurs first (up to approximately 35 months) |
Countries
China
Outcome results
None listed